Nurse Practitioner Program year 2024 Reported 2021–2024 Source: CMS Open Payments, 2026 publication

Michael Munn

Nurse Practitioner Mountain Home, AR Nurse Practitioner

NPI 1720612641 CMS profile 11105861

17 Medical Plz, Mountain Home, AR 72653

Open in the dashboard

General payments

$1,175

10 records reported · program years 2021–2024

Research payments

$0

Paid to them · None reported · program years 2021–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Michael Munn of Mountain Home, AR is reported in the CMS Open Payments database as having received $1,175 across 10 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 72nd percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $140 3
2023 General $971 3
2022 General $52 3
2021 General $12 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Munn
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Michael Munn were reported at $0. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Michael Munn Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $12 $135 $40–$426 $132
2022 $52 $152 $48–$470 $149
2023 $971 $166 $54–$529 $160
2024 $140 $173 $55–$556 $164
2025 $0 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2024
  1. Boston Scientific Corporation $1,059 4 payments
  2. SPR Therapeutics, Inc $36 1 payment
  3. Lilly USA, LLC $20 1 payment
  4. Organon LLC $17 1 payment
  5. Medtronic, Inc. $17 1 payment
  6. KCI USA, Inc $15 1 payment
  7. Genentech USA, Inc. $12 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2024
  1. Travel and Lodging $774 2 payments
  2. Food and Beverage $401 8 payments
Products named General payments · program years 2021–2024
  1. Superion Indirect Decompression System $87 1 payment
  2. SPRINT PNS System $36 1 payment
  3. JARDIANCE $20 1 payment
  4. TRULICITY $20 1 payment
  5. NEXPLANON $17 1 payment
  6. PREVENA $15 1 payment
  7. V.A.C. VERAFLO CLEANSE CHOICE $15 1 payment
  8. V.A.C.ULTA $15 1 payment
  9. Xofluza $12 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 39 drugs

Part D claims

6,129

Median for Nurse Practitioner: 389

Drug cost

$276,862

Median for Nurse Practitioner: $21,885

Branded share of claims

40.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 1,890 $43,662
Ubrelvy Ubrogepant Brand 13 $36,193
Buprenorphine Generic 117 $31,134
Belbuca Buprenorphine Hcl Brand 36 $22,742
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 101 $18,739
Qulipta Atogepant Brand 16 $16,618
Suboxone Buprenorphine Hcl/Naloxone Hcl Brand 20 $12,359
Zubsolv Buprenorphine Hcl/Naloxone Hcl Brand 11 $9,573
Movantik Naloxegol Oxalate Brand 22 $8,946
Linzess Linaclotide Brand 15 $7,954

The 10 drugs with the highest cost, of 39 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$13,127

Medicare's payments for the services billed

Medicare patients

150

Average age 70

Services billed

352

86 women, 64 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 42%
COPD 32%
Ischemic heart disease 27%
Diabetes 25%
Heart failure 20%
Osteoporosis 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

10 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record